BioLineRx Income Statement (2023-2025) | BLRX

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue -0.63M0.84M1.02M6.86M5.39M4.94M11.75M0.26M0.30M0.43M
Cost of Revenue 3.87M5.60M8.13M-13.92M1.46M0.90M0.82M6.09M0.03M0.07M0.08M
Gross Profit 5.40M4.50M4.12M5.66M0.22M0.23M0.34M
Operating items
Research & Development -3.68M-3.01M-2.73M-3.10M-2.49M-2.23M-2.56M-1.86M-1.62M-2.33M-1.72M
Share-based Compensation (IS) 0.43M0.48M0.47M0.93M0.53M0.44M0.32M-0.15M0.19M0.05M0.10M
Selling, General & Administrative -1.30M-1.30M-1.50M-2.21M-1.39M-1.63M-1.39M-1.92M-0.99M-0.21M-0.83M
Operating Expenses -4.98M-4.31M-4.23M-5.31M-3.88M-3.85M-3.96M-3.78M-2.61M-2.54M-2.55M
Operating Income -8.86M-9.91M-12.36M-18.57M-4.82M-5.77M-5.39M-4.43M-2.39M-2.30M-2.21M
EBIT -8.86M-9.91M-12.36M-18.57M-4.82M-5.77M-5.39M-4.43M-2.39M-2.30M-2.21M
Non-operating items
Non Operating Income -2.92M-7.73M-3.14M2.97M4.49M7.81M0.76M5.38M7.64M-1.85M1.16M
Net income details
EBT -9.49M-8.58M-11.52M-17.54M-3.89M-3.69M-3.76M-7.94M-1.97M-2.03M-1.90M
Profit After Tax -12.16M18.55M-16.02M-17.54M-0.70M0.48M-5.82M-7.94M5.13M3.94M-0.98M
Income from Continuing Operations -9.49M-8.58M-11.52M-17.54M-3.89M-3.69M-3.76M-7.94M-1.97M-2.03M-1.90M
Consolidated Net Income -9.49M-8.58M-11.52M-17.54M-3.89M-3.69M-3.76M-7.94M-1.97M-2.03M-1.90M
Income towards Parent Company -9.49M-8.58M-11.52M-17.54M-3.89M-3.69M-3.76M-7.94M-1.97M-2.03M-1.90M
Net Income towards Common Stockholders -9.49M-8.58M-11.52M-17.54M-3.89M-3.69M-3.76M-7.94M-1.97M-2.03M-1.90M
Additional items
EPS (Basic) -0.010.02-0.02
EPS (Weighted Average and Diluted) 0.02
EBITDA -1.42M-1.42M-1.42M-1.42M-0.70M-1.42M-1.42M-3.19M-1.42M-1.42M-1.42M
Interest Expenses 0.63M-1.34M-0.84M-1.02M-0.93M-2.08M-1.62M3.51M-0.42M-0.28M-0.30M